<div id="readability-page-1">BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best NASDAQ stocks to buy in 2026. On December 22, H.C. Wainwright raised the firm’s price target on BioMarin to $60 from $55 with a Neutral rating on the shares. This sentiment was announced amid the acquisition of Amicus Therapeutics Inc. (NASDAQ:FOLD), which the firm described as […]</div>

拜玛林制药

<p>H.C. Wainwright 将 BioMarin Pharmaceutical Inc.（NASDAQ:BMRN）的目标股价从 55 美元上调至 60 美元，维持中性评级。这一调整是基于 BioMarin 收购 Amicus Therapeutics Inc.（NASDAQ:FOLD）的背景，预计该收购将稳定现金流，同时 Voxzogo 被预期为短期增长驱动因素。BioMarin 被认为是 2026 年值得购买的顶级 NASDAQ 股票之一</p>

HC Wainwright 表示，BioMarin 的收购 Amicus 稳定了现金流，而 Voxzogo 仍然是近期的主要驱动因素